Veradermics (NYSE: MANE) has recently received a number of price target changes and ratings updates:
- 7/16/2026 – Veradermics had its price target raised by Citigroup Inc. from $135.00 to $160.00. They now have a “buy” rating on the stock.
- 7/15/2026 – Veradermics was given a new $170.00 price target by UBS Group AG.
- 7/15/2026 – Veradermics is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $170.00 price target on the stock.
- 7/15/2026 – Veradermics had its price target raised by Needham & Company LLC from $136.00 to $164.00. They now have a “buy” rating on the stock.
- 7/12/2026 – Veradermics was downgraded by Wall Street Zen from “hold” to “sell”.
- 7/7/2026 – Veradermics had its price target raised by Jefferies Financial Group Inc. from $138.00 to $182.00. They now have a “buy” rating on the stock.
- 6/16/2026 – Veradermics is now covered by Lifesci Capital. They set an “outperform” rating and a $135.00 price target on the stock.
- 6/14/2026 – Veradermics was upgraded by Wall Street Zen from “sell” to “hold”.
- 6/6/2026 – Veradermics was downgraded by Wall Street Zen from “hold” to “sell”.
- 6/2/2026 – Veradermics is now covered by Needham & Company LLC. They set a “buy” rating and a $136.00 price target on the stock.
We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.
Featured Stories
- Five stocks we like better than Veradermics
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
- Tesla: After a Rough Quarter, 2 Very Different Futures Come Into Focus
Receive News & Ratings for Veradermics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradermics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.
